Summary
(1) The mean cumulative urinary digoxin excretion over 8 days was compared in 8 healthy volunteers after single doses of digoxin administered as 3 Lanoxin tablets of 0.25 mg, 3 digoxin tablets of 0.2 mg, 12 Lanoxicaps without sorbitol of 0.05 mg, 6 Lanoxicaps without sorbitol of 0.1 mg digoxin, 3 Lanoxicaps without sorbitol of 0.2 mg and 3 Lanoxicaps with sorbitol of 0.2 mg. (2) There was no significant difference between the 8 day cumulative urinary excretion for any of the Lanoxicaps treatments. (3) Cumulative urinary excretion after 3 digoxin tablets of 0.2 mg was significantly (P<0.05) lower than after all other treatments. (4) Cumulative urinary excretion after 3 Lanoxin tablets of 0.25 mg was not significantly different from that after any of the Lanoxicaps treatments except 0.1 mg Lanoxicaps without sorbitol, it was significantly (P<0.05) lower after the latter. (5) Mean urinary excretion of digoxin was 60% of ingested dose for all Lanoxicaps treatments and was significantly (P<0.05) higher than the mean value of 50% for both tablet treatments. (6) Enhanced absorption of digoxin from Lanoxicaps was confirmed and shown to be unrelated to the sorbitol content of the capsule shell.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Binnion, F.: A comparison of the bioavailability of digoxin in capsule, tablet and solution taken orally with intravenous digoxin. J. clin. Pharmacol.16, 461–467 (1976)
Greenblatt, D. J., Duhme, D. W., Koch-Weser, J., Smith, T. W.: Evaluation of Digoxin Bioavailability in single-dose studies. N. Eng. J. Med.289, 651–654 (1973)
Johnson, B. F., Bye, C.: Maximal intestinal absorption of digoxin, and its relation to steady state plasma concentration. Brit. Heart J.37, 203–208 (1975)
Johnson, B. F., Bye, C., Jones, G., Sabey, G. A.: A completely absorbed oral preparation of digoxin. Clin. Pharmacol. Ther.19/6, 746–751 (1976)
Johnson, B. F., Smith, G., French, J.: The comparability of dosage regimens of Lanoxin tablets and Lanoxicaps. Brit. J. clin. Pharmacol.4, 209–211 (1977)
Lindenbaum, J.: Greater bioavailability of digoxin solution in capsules. Clin. Pharmacol. Ther.21/3, 278–282 (1977)
Mallis, G. I., Schmidt, D. H., Lindenbaum, J.: Superior bioavailability of digoxin solution in capsules. Clin. Pharmacol. Ther.18/6, 761–768 (1975)
Marcus, F. I., Dickerson, J., Pippin, S., Stafford, M., Bressler, R.: Digoxin bioavailability: Formulations and rates of infusion. Clin. Pharmacol. Ther.20, 253–259 (1976)
O'Grady, J., Johnson, B. F., Bye, C., Sabey, G. A.: Influence of soft gelatin on digoxin absorption. Brit. J. clin. Pharmacol.5, 461–463 (1978)
Rodgers, E. M., Dobbs, M., Kenyon, W. I., Poston, J. W.: Evaluation of digoxin capsules in outpatients. Brit. med. J.1977/I, 234–235
Sanchez, N., Sheiner, L. B., Halkin, H., Melmon, K. L.: Pharmacokinetics of Digoxin: Interpreting Bioavailability. Brit. Med. J.1973/IV, 132–134
Author information
Authors and Affiliations
Additional information
Trade marks
Rights and permissions
About this article
Cite this article
O'Grady, J., Johnson, B.F., Bye, C. et al. The comparative bioavailability of Lanoxin tablets and Lanoxicaps with and without sorbitol. Eur J Clin Pharmacol 14, 357–360 (1978). https://doi.org/10.1007/BF00611906
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00611906